Description
Global PD-1/PDL-1 Inhibitor Market Overview
Programmed cell death 1 (PD-1) inhibitor and programmed death ligand 1 (PD-L1) inhibitor are therapeutic agents that inhibit binding together of these checkpoint proteins on immune cells, eventually preventing tumors to escape the host immune defense mechanism and control the disease progression. The first PD-1 inhibitor Opdivo developed by Merck Sharp and Dhome (MSD) entered the market in 2014. Jemperli from GSK is the latest market entrant in the segment.
The current market already has seven approved products in the U.S. and a large number of research activities are currently undergoing in this segment generating interest of commercial as well as academic research institutions. In the current period of precision medicine and providing targeted treatment, identification of target patient has become very important as well as complicated. With the emergence of diagnostic test identifying predictive biomarkers, the selection and administration of targeted treatment has become comparativlely conveninent and efficient.
PD-1/PDL-1 inhibitors are majorly indicated for the treatment of advanced cases of different cancer indications. The PD-1/PDL-1 inibitor treatment has been found to be more effective in patients demonstrating certain level of predictive biomarkers such as PDL-1 expression. However, these tests are costly and treatment specific which poses a hinderance to smooth administration of these PD-1/PDL-1 inhibitors to larger set of patients.
Several players, such as MSD, Bristol Myers Squibb company (BMS), AstraZeneca Plc are among the leading companies actively pursuing research activities in maximizing the potential of PD-1/PDL-1 inhbitors. Companies in the Asia-Pacific region also have rich clinical pipeline and strategically pursuing research activities in this segment.
Competitive Landscape
There are seven product currently available in the market. The first entrant Keytruda drwas a significant share of the market followed by second entrant Opdivo. Imfinzi and Tecentriq also have their combined market share below 20%.
Disease Landscape
In terms of most promising indication for the application of PD-1/PDL-1 inhibitors, melanoma appears to be leading as highlighted by experts including data gathered from secondary research.
Segmentation:
Within the research report, the segmentation has made on the basis of:
• Identified cancer indicattions (Non-small cell lung cancer, melanoma, breast cancer, hepatocellular carcinoma, colorectal cancer, and urothelial carcinoma), and
• The seven major markets (the U.S., the U.K., Germany, France, Italy, Spain, and Japan).
This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, and future opportunities, among others, to detail the scope and provide a 360-coverage of the domain.
Demand – Drivers and Challenges
Some of the potential drivers includes:
• Increased Use of PD-1/PDL-1 Inhibitors in Multiple Sub-set of Cancer Indications
• Increase in PD-1/PDL-1 Inhibitor Based Combination Regimens
The market is expected to face some limitations too due to the following challenges:
• Immune-related Adverse Events Associated With PD-1/PDL-1 Inhibitor Treatment are a Cause of Concern
• Treatment Specific Biomarkers Assays Pose Hinderance to Smooth Adoption of PD-1/PDL-1 Inhibitor Treatment
How can this report add value to an organization?
Product/Innovation Strategy: The report provides an exhaustive list of pipeline products which are currently in the development along with their developmental details in various indications. This can help organizations in understanding the research activities, which is the promising indication to pursue or which organization has the potential product to enter first into the market as well it can help the organization to assess where should they place themselves in order to get maximum benefit. This report which provides an insight into estimated patient population eligible to receive PD-1/PDL-1 under identified indications will help to evaluate the promising indications.
Growth/Marketing Strategy: In addition to pursuing research on exploring the benefits of PD-1/PDL-1 inhibitors in multiple cancer indications, companies are working to bring more safer and convenient PD-1/PDL-1 inhbitors while retaining or improved efficacy. The companies are exploring small molecules as well as alternative formulations for PD-1/PDL-1 inhibitors in an effort to make the administration relatively more convenient.
Competitive Strategy: Key players in the global PD-1/PDL-1 inhibitor market were analyzed and profiled in the study, who have commercially available PD-1/PDL-1 inhbitors as well as those who are developing and their products are in the clinical development. Moreover, a detailed competitive benchmarking of the players operating in the global PD-1/PDL-1 inhibitor market has been done to help the reader understand how players stand against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Companies Profiled
• GlaxoSmithKline plc
• Bristol-Myers Squibb Company
• Arcus Biosciences, Inc.
• Agenus Inc.
• F. Hoffmann-La Roche Ltd
• Astra Zeneca PLC
• Beigene Ltd.
• Shanghai Junshi Bioscience Co. Ltd.
• Shanghai Henlius Biotech, Inc.
• Jiangsu HengRui Medicine Co., Ltd.
• Lee’s Pharmaceutical Limited
• Incyte Corporation
• Biocad
• CStone Pharmaceuticals
Table of Contents
1 Market Definition
1.1 Inclusion and Exclusion Criteria
2 Research Scope
2.1 Target Audience
2.2 Key Questions Answered in the Report
3 Research Methodology
3.1 Global PD-1/PDL-1 Inhibitor Market: Research Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Target Patient Pool Estimation Model
3.5 Criteria for Company Profiling
4 Markets
4.1 Market Overview
4.2 PD-1/PDL-1 Inhibitors: Overview
4.2.1 PD-1/PDL-1 Inhibitors and their role in Cancer immunotherapy
4.2.2 Historic Development of PD-1/PDL-1 Inhibitors
4.2.3 Mechanism of Action of PD-1/PDL-1 Inhibitors
4.2.4 Market Landscape
4.2.4.1 Approved PD-1/PDL-1 Inhibitors
4.2.4.2 Competitive Landscape
4.2.4.2.1 Strategic Activities
4.2.4.2.2 Regional Distribution of Companies
4.2.5 Market Dynamics
4.2.5.1 Market Drivers
4.2.5.1.1 Increased Use of PD-1/PDL-1 Inhibitors in Multiple Sub-set of Cancer Indications
4.2.5.1.2 Increase in PD-1/PDL-1 Inhibitor Based Combination Regimens
4.2.5.2 Market Restraints
4.2.5.2.1 Immune-related Adverse Events Associated With PD-1/PDL-1 Inhibitor Treatment are a Cause of Concern
4.2.5.2.2 Treatment Specific Biomarkers Assays Pose Hinderance to Smooth Adoption of PD-1/PDL-1 Inhibitor Treatment
4.2.5.3 Opportunities
4.2.5.3.1 Promising Therapeutic Outcomes Generating Positive Market Sentiments
4.2.5.3.2 Demand for Safer and Convenient Formulation
5 Indications
5.1 Indications
5.1.1 Non-Small Cell Lung Cancer (NSCLC)
5.1.1.1 Non-Small Cell Lung Cancer (NSCLC): Disease Overview
5.1.1.2 Non-Small Cell Lung Cancer (NSCLC): Disease Pathophysiology
5.1.1.3 Non-Small Cell Lung Cancer (NSCLC): Treatment
5.1.2 Melanoma
5.1.2.1 Melanoma: Disease Overview
5.1.2.2 Melanoma: Disease Pathophysiology
5.1.2.3 Melanoma: Treatment
5.1.3 Hepatocellular Carcinoma (HCC)
5.1.3.1 Hepatocellular Carcinoma (HCC): Disease Overview
5.1.3.2 Hepatocellular Carcinoma (HCC): Disease Pathophysiology
5.1.3.3 Hepatocellular Carcinoma (HCC): Treatment
5.1.4 Colorectal Cancer (CRC)
5.1.4.1 Colorectal Cancer (CRC): Disease Overview
5.1.4.2 Colorectal Cancer (CRC): Disease Pathophysiology
5.1.4.3 Colorectal Cancer (CRC): Treatment
5.1.5 Breast Cancer
5.1.5.1 Breast Cancer: Disease Overview
5.1.5.2 Breast Cancer: Pathophysiology
5.1.5.3 Breast Cancer: Treatment
5.1.6 Urothelial Carcinoma
5.1.6.1 Urothelial Carcinoma: Disease Overview
5.1.6.2 Urothelial Carcinoma: Pathophysiology
5.1.6.3 Urothelial Carcinoma: Treatment
6 Products
6.1 Global PD-1/PDL-1 Inhibitor Pipeline Analysis (by Phase)
6.1.1 By Development Phase
6.1.2 By Drug Class
6.1.3 By Route of Administration (RoA)
6.1.4 By Monotherapy/Combination Therapy Type
6.1.5 By Target
7 Application
7.1 North America
7.1.1 Melanoma
7.1.1.1 Melanoma: Epidemiology
7.1.2 Breast Cancer
7.1.2.1 Breast Cancer: Epidemiology
7.1.3 Colorectal Cancer (CRC)
7.1.3.1 Colorectal Cancer (CRC): Epidemiology
7.1.4 Non-Small Cell Lung Cancer (NSCLC)
7.1.4.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology
7.1.5 Hepatocellular Carcinoma (HCC)
7.1.5.1 Hepatocellular Carcinoma (HCC): Epidemiology
7.1.6 Urothelial Carcinoma
7.1.6.1 Urothelial Carcinoma: Epidemiology
7.2 U.K.
7.2.1 Non-Small Cell Lung Cancer (NSCLC)
7.2.1.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology
7.2.2 Melanoma
7.2.2.1 Melanoma: Epidemiology
7.2.3 Hepatocellular Carcinoma (HCC)
7.2.3.1 Hepatocellular Carcinoma (HCC): Epidemiology
7.2.4 Colorectal Cancer (CRC)
7.2.4.1 Colorectal Cancer (CRC): Epidemiology
7.2.5 Breast Cancer
7.2.5.1 Breast Cancer: Epidemiology
7.2.6 Urothelial Carcinoma
7.2.6.1 Urothelial Carcinoma: Epidemiology
7.3 Germany
7.3.1 Non-Small Cell Lung Cancer (NSCLC)
7.3.1.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology
7.3.2 Melanoma
7.3.2.1 Melanoma: Epidemiology
7.3.3 Hepatocellular Carcinoma (HCC)
7.3.3.1 Hepatocellular Carcinoma (HCC): Epidemiology
7.3.4 Colorectal Cancer (CRC)
7.3.4.1 Colorectal Cancer (CRC): Epidemiology
7.3.5 Breast Cancer
7.3.5.1 Breast Cancer: Epidemiology
7.3.6 Urothelial Carcinoma
7.3.6.1 Urothelial Carcinoma: Epidemiology
7.4 France
7.4.1 Non-Small Cell Lung Cancer (NSCLC)
7.4.1.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology
7.4.2 Melanoma
7.4.2.1 Melanoma: Epidemiology
7.4.3 Hepatocellular Carcinoma (HCC)
7.4.3.1 Hepatocellular Carcinoma (HCC): Epidemiology
7.4.4 Colorectal Cancer (CRC)
7.4.4.1 Colorectal Cancer (CRC): Epidemiology
7.4.5 Breast Cancer
7.4.5.1 Breast Cancer: Epidemiology
7.4.6 Urothelial Carcinoma
7.4.6.1 Urothelial Carcinoma: Epidemiology
7.5 Italy
7.5.1 Non-Small Cell Lung Cancer (NSCLC)
7.5.1.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology
7.5.2 Melanoma
7.5.2.1 Melanoma: Epidemiology
7.5.3 Hepatocellular Carcinoma (HCC)
7.5.3.1 Hepatocellular Carcinoma (HCC): Epidemiology
7.5.4 Colorectal Cancer (CRC)
7.5.4.1 Colorectal Cancer (CRC): Epidemiology
7.5.5 Breast Cancer
7.5.5.1 Breast Cancer: Epidemiology
7.5.6 Urothelial Carcinoma
7.5.6.1 Urothelial Carcinoma: Epidemiology
7.6 Spain
7.6.1 Non-Small Cell Lung Cancer (NSCLC)
7.6.1.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology
7.6.2 Melanoma
7.6.2.1 Melanoma: Epidemiology
7.6.3 Hepatocellular Carcinoma (HCC)
7.6.3.1 Hepatocellular Carcinoma (HCC): Epidemiology
7.6.4 Colorectal Cancer (CRC)
7.6.4.1 Colorectal Cancer (CRC): Epidemiology
7.6.5 Breast Cancer
7.6.5.1 Breast Cancer: Epidemiology
7.6.6 Urothelial Carcinoma
7.6.6.1 Urothelial Carcinoma: Epidemiology
7.7 Japan
7.7.1 Non-Small Cell Lung Cancer (NSCLC)
7.7.1.1 Non-Small Cell Lung Cancer (NSCLC): Epidemiology
7.7.2 Melanoma
7.7.2.1 Melanoma: Epidemiology
7.7.3 Hepatocellular Carcinoma (HCC)
7.7.3.1 Hepatocellular Carcinoma (HCC): Epidemiology
7.7.4 Colorectal Cancer (CRC)
7.7.4.1 Colorectal Cancer (CRC): Epidemiology
7.7.5 Breast Cancer
7.7.5.1 Breast Cancer: Epidemiology
7.7.6 Urothelial Carcinoma
7.7.6.1 Urothelial Carcinoma: Epidemiology
8 Markets – Competitive Benchmarking & Company Profiles
8.1 GlaxoSmithKline plc
8.1.1 Company Overview
8.1.2 Role of GlaxoSmithKline plc in Global PD-1/PDL-1 Inhibitor Market
8.1.3 Product Portfolio
8.1.4 Key Competitors of the Company
8.1.5 Financials
8.1.6 Key Insights About Financial Health of the Company
8.1.7 Business Strategies
8.1.7.1 Product Developments
8.1.8 Corporate Strategies
8.1.8.1 Partnership and Collaboration
8.1.9 Analyst’s Perspective
8.2 Bristol-Myers Squibb Company
8.2.1 Company Overview
8.2.2 Role of Bristol-Myers Squibb Company in Global PD-1/PDL-1 Inhibitor Market
8.2.3 Product Portfolio
8.2.4 Key Competitors of the Company
8.2.5 Financials
8.2.6 Key Insights About Financial Health of the Company
8.2.7 Business Strategies
8.2.7.1 Product Developments
8.2.8 Corporate Strategies
8.2.8.1 Merger and Acquisitions
8.2.9 Analyst’s Perspective
8.3 Arcus Biosciences, Inc.
8.3.1 Company Overview
8.3.2 Role of Arcus Biosciences, Inc. in Global PD 1/PDL-1 inhibitor Market
8.3.3 Product Portfolio
8.3.4 Key Competitors of the Company
8.3.5 Financials
8.3.6 Key Insights About Financial Health of the Company
8.3.7 Business Strategies
8.3.7.1 Product Developments
8.3.8 Corporate Strategies
8.3.8.1 Partnerships and Collaboration
8.3.9 Analyst’s Perspective
8.4 Agenus Inc.
8.4.1 Company Overview
8.4.2 Role of Agenus Inc. in Global PD 1/PDL-1 Inhibitor Market
8.4.3 Product Portfolio
8.4.4 Financials
8.4.5 Key Insights About Financial Health of the Company
8.4.6 Business Strategies
8.4.6.1 Product Developments
8.4.7 Corporate Strategies
8.4.7.1 Partnerships and Collaboration
8.4.8 Analyst’s Perspective
8.5 F. Hoffmann-La Roche Ltd
8.5.1 Company Overview
8.5.2 Role of F. Hoffmann-La Roche Ltd in Global PD 1/PDL-1 inhibitor Market
8.5.3 Product Portfolio
8.5.4 Key Competitors of the Company
8.5.5 Financials
8.5.6 Key Insights About Financial Health of the Company
8.5.7 Business Strategies
8.5.7.1 Product Developments
8.5.8 Corporate Strategies
8.5.8.1 Partnership and Collaboration
8.5.9 Analyst’s Perspective
8.6 Astra Zeneca PLC
8.6.1 Company Overview
8.6.2 Role of Astra Zeneca PLC in Global PD 1/PDL-1 inhibitor Market
8.6.3 Product Portfolio
8.6.4 Key Competitors of the Company
8.6.5 Financials
8.6.6 Key Insights About Financial Health of the Company
8.6.7 Business Strategies
8.6.7.1 Product Developments
8.6.8 Corporate Strategies
8.6.8.1 Partnership and Collaboration
8.6.9 Analyst’s Insight
8.7 Beigene Ltd.
8.7.1 Company Overview
8.7.2 Role of Beigene Ltd. in Global PD 1/PDL-1 inhibitor Market
8.7.3 Product Portfolio
8.7.4 Key Competitors of the Company
8.7.5 Financials
8.7.6 Key Insights About Financial Health of the Company
8.7.7 Business Strategies
8.7.7.1 Product Developments
8.7.8 Corporate Strategies
8.7.8.1 Partnership and Collaboration
8.7.9 Analyst’s Perspective
8.8 Shanghai Junshi Bioscience Co. Ltd.
8.8.1 Company Overview
8.8.2 Role of Shanghai Junshi Bioscience Co., Ltd. in Global PD 1/PDL-1 inhibitor Market
8.8.3 Product Portfolio
8.8.4 Key Competitors of the Company
8.8.5 Financials
8.8.6 Key Insights About Financial Health of the Company
8.8.7 Business Strategies
8.8.7.1 Product Developments
8.8.8 Corporate Strategies
8.8.8.1 Partnership and Collaboration
8.8.9 Analyst’s Perspective
8.9 Shanghai Henlius Biotech, Inc.
8.9.1 Company Overview
8.9.2 Role of Shanghai Henlius Biotech, Inc. in Global PD 1/PDL-1 inhibitor Market
8.9.3 Product Portfolio
8.9.4 Key Competitors of the Company
8.9.5 Financials
8.9.6 Key Insights About Financial Health of the Company
8.9.7 Business Strategies
8.9.7.1 Product Developments
8.9.8 Corporate Strategies
8.9.8.1 Partnership and Collaboration
8.9.9 Analyst’s Perspective
8.1 Jiangsu HengRui Medicine Co., Ltd.
8.10.1 Company Overview
8.10.2 Role of Jiangsu HengRui Medicine Co., Ltd. in Global PD 1/PDL-1 Inhibitor Market
8.10.3 Product Portfolio
8.10.4 Key Competitors of the Company
8.10.5 Financials
8.10.6 Key Insights About Financial Health of the Company
8.10.7 Business Strategies
8.10.7.1 Product Developments
8.10.8 Corporate Strategies
8.10.8.1 Partnership and Collaboration
8.10.9 Analyst’s Perspective
8.11 Lee’s Pharmaceutical Limited
8.11.1 Company Overview
8.11.2 Role of Lee’s Pharmaceutical Limited in Global PD 1/PDL-1 inhibitor Market
8.11.3 Product Portfolio
8.11.4 Key Competitors of the Company
8.11.5 Financials
8.11.6 Key Insights About Financial Health of the Company
8.11.7 Business Strategies
8.11.7.1 Product Developments
8.11.8 Analyst’s Perspective
8.12 Incyte Corporation
8.12.1 Company Overview
8.12.2 Role of Incyte Corporation in Global PD-1/PDL-1 inhibitors Market
8.12.3 Product Portfolio
8.12.4 Key Competitors of the Company
8.12.5 Financials
8.12.6 Key Insights About Financial Health of the Company
8.12.7 Business Strategies
8.12.7.1 Product Developments
8.12.8 Corporate Strategies
8.12.8.1 Collaboration and Agreement
8.12.9 Analyst’s Perspective
8.13 Biocad
8.13.1 Company Overview
8.13.2 Role of Biocad in Global PD-1/PDL-1 Inhibitors Market
8.13.3 Product Portfolio
8.13.4 Key Competitors of the Company
8.13.5 Business Strategies
8.13.5.1 Product Developments
8.13.6 Corporate Strategies
8.13.6.1 Partnership and Collaboration
8.13.7 Analyst’s Perspective
8.14 CStone Pharmaceuticals
8.14.1 Company Overview
8.14.2 Role of CStone Pharmaceuticals in Global PD-1/PDL-1 Inhibitors Market
8.14.3 Product Portfolio
8.14.4 Key Competitors of the Company
8.14.5 Financials
8.14.6 Key Insights About Financial Health of the Company
8.14.7 Business Strategies
8.14.7.1 Product Developments
8.14.8 Corporate Strategies
8.14.8.1 Partnership and Collaboration
8.14.9 Analyst’s Perspective
9 BIS Research Recommendations
9.1 Current Market Scenario
9.2 Future Scenario
9.3 Key Success Factors and Challenges
9.3.1 Success Factors
9.3.2 Key Challenges
List of Figures
Figure 1: PD-1/PDL-1 Inhibitor Market Share (by Sales), $Million, 2021
Figure 2: Number of Eligible Patients Specific to Indication for 2022
Figure 3: Global PD-1/PDL-1 Inhibitor Market Segmentation
Figure 4: Global PD-1/PDL-1 Inhibitor Market Methodology
Figure 5: Primary Research Methodology
Figure 6: Historic Development of PD-1/PDL-1 Inhibitors
Figure 7: Role of PD-1/PDL-1 in Tumor Protection
Figure 8: Key Market Players (by Sales), $Million, 2021
Figure 9: Number of Strategic Activities
Figure 10: Regional Distribution of Companies
Figure 11: Non-Small Cell Lung Cancer (NSCLC) Disease Pathophysiology
Figure 12: Melanoma Disease Pathophysiology
Figure 13: Melanoma: Treatment Options
Figure 14: Hepatocellular Carcinoma (HCC): Disease Pathophysiology
Figure 15: Hepatocellular Carcinoma (HCC) Treatment
Figure 16: Hepatocellular Carcinoma (HCC) Treatment Algorithm
Figure 17: Chromosomal Instability (CIN) Pathway and Microsatellite Instability (MSI) Pathway
Figure 18: Serrated Pathway
Figure 19: Colorectal Cancer (CRC): Treatment Algorithm
Figure 20: Breast Cancer: Disease Pathophysiology
Figure 21: Breast Cancer: Treatment
Figure 22: Urothelial Carcinoma: Disease Pathophysiology
Figure 23: Urothelial Carcinoma Treatment Types
Figure 24: Urothelial Carcinoma Treatment Algorithm
Figure 25: Number of PD-1/PDL-1 Inhibitor Clinical Trials
Figure 26: Number of Clinical Trials by Drug Class
Figure 27: PD-1/PDL-1 Inhibitor by Therapy (Monotherapy/Combination) Type
Figure 28: PD-1/PDL-1 Inhibitors with Added Entity
Figure 29: U.S. Eligible Population for PD-1/PDL-1 Inhibitor Treatment
Figure 30: U.S. Eligible Patient Population for Melanoma, 2022-2032
Figure 31: U.S. Eligible Patient Population for Breast Cancer, 2022-2032
Figure 32: U.S. Eligible Patient Population for Colorectal Cancer, 2022-2032
Figure 33: U.S. Eligible Patient Population for NSCLC, 2022-2032
Figure 34: U.S. Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032
Figure 35: U.S. Eligible Patient Population for Urothelial Carcinoma, 2022-2032
Figure 36: U.K. Eligible Population for PD-1/PDL-1 Inhibitor Treatment
Figure 37: U.K. Eligible Patient Population for NSCLC, 2022-2032
Figure 38: U.K. Eligible Patient Population for Melanoma, 2022-2032
Figure 39: U.K. Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032
Figure 40: U.K. Eligible Patient Population for Colorectal Cancer, 2022-2032
Figure 41: U.K. Eligible Patient Population for Breast Cancer, 2022-2032
Figure 42: U.K. Eligible Patient Population for Urothelial Carcinoma, 2022-2032
Figure 43: Germany Eligible Population for PD-1/PDL-1 Inhibitor Treatment
Figure 44: Germany: Eligible Patient Population for NSCLC, 2022-2032
Figure 45: Germany: Eligible Patient Population for Melanoma, 2022-2032
Figure 46: Germany: Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032
Figure 47: Germany: Eligible Patient Population for Colorectal Cancer, 2022-2032
Figure 48: Germany: Eligible Patient Population for Breast Cancer, 2022-2032
Figure 49: Germany: Eligible Patient Population for Urothelial Carcinoma, 2022-2032
Figure 50: France Eligible Population for PD-1/PDL-1 Inhibitor Treatment
Figure 51: France: Eligible Patient Population for NSCLC, 2022-2032
Figure 52: France: Eligible Patient Population for Melanoma, 2022-2032
Figure 53: France: Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032
Figure 54: France: Eligible Patient Population for Colorectal Cancer, 2022-2032
Figure 55: France: Eligible Patient Population for Breast Cancer, 2022-2032
Figure 56: France: Eligible Patient Population for Urothelial Carcinoma, 2022-2032
Figure 57: Italy Eligible Population for PD-1/PDL-1 Inhibitor Treatment
Figure 58: Italy: Eligible Patient Population for NSCLC, 2022-2032
Figure 59: Italy: Eligible Patient Population for Melanoma, 2022-2032
Figure 60: Italy: Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032
Figure 61: Italy: Eligible Patient Population for Colorectal Cancer, 2022-2032
Figure 62: Italy: Eligible Patient Population for Breast Cancer, 2022-2032
Figure 63: Italy: Eligible Patient Population for Urothelial Carcinoma, 2022-2032
Figure 64: Spain Eligible Population for PD-1/PDL-1 Inhibitor Treatment
Figure 65: Spain: Eligible Patient Population for NSCLC, 2022-2032
Figure 66: Spain: Eligible Patient Population for Melanoma, 2022-2032
Figure 67: Spain: Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032
Figure 68: Spain: Eligible Patient Population for Colorectal Cancer, 2022-2032
Figure 69: Spain: Eligible Patient Population for Breast Cancer, 2022-2032
Figure 70: Spain: Eligible Patient Population for Urothelial Carcinoma, 2022-2032
Figure 71: Japan Eligible Population for PD-1/PDL-1 Inhibitor Treatment
Figure 72: Japan: Eligible Patient Population for NSCLC, 2022-2032
Figure 73: Japan: Eligible Patient Population for Melanoma, 2022-2032
Figure 74: Japan: Eligible Patient Population for Hepatocellular Carcinoma, 2022-2032
Figure 75: Japan: Eligible Patient Population for Colorectal Cancer, 2022-2032
Figure 76: Japan: Eligible Patient Population for Breast Cancer, 2022-2032
Figure 77: Japan: Eligible Patient Population for Urothelial Carcinoma, 2022-2032
Figure 78: GlaxoSmithKline plc: Product Portfolio
Figure 79: GlaxoSmithKline plc: Overall Financials, $Million, 2019-2021
Figure 80: GlaxoSmithKline plc: Net Revenue (by Segment), $Million, 2019-2021
Figure 81: GlaxoSmithKline plc: Net Revenue (by Region), $Million, 2019-2021
Figure 82: GlaxoSmithKline plc: R&D Expenditure, $Million, 2019-2021
Figure 83: Bristol-Myers Squibb Company: Product Portfolio
Figure 84: Bristol-Myers Squibb Company: Overall Financials, $Million, 2019-2021
Figure 85: Bristol-Myers Squibb Company: Net Revenue (by Region), $Million, 2019-2021
Figure 86: Bristol-Myers Squibb Company: R&D Expenditure, $Million, 2019-2021
Figure 87: Arcus Biosciences, Inc.: Product Portfolio
Figure 88: Arcus Biosciences, Inc.: Overall Financials, $Million, 2019-2021
Figure 89: Arcus Biosciences, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 90: Agenus Inc.: Product Portfolio
Figure 91: Agenus Inc.: Overall Financials, $Million, 2019-2021
Figure 92: Agenus Inc.: Net Revenue (by Region), $Million, 2019-2021
Figure 93: Agenus Inc.: R&D Expenditure, $Million, 2019-2021
Figure 94: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 95: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021
Figure 96: F. Hoffmann-La Roche Ltd: Net Revenue (by Segment), $Million, 2019-2021
Figure 97: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021
Figure 98: Astra Zeneca PLC: Product Portfolio
Figure 99: Astra Zeneca PLC: Overall Financials, $Million, 2019-2021
Figure 100: Astra Zeneca PLC: Net Revenue (by Region), $Million, 2019-2021
Figure 101: Astra Zeneca PLC: R&D Expenditure, $Million, 2019-2021
Figure 102: Beigene Ltd.: Product Portfolio
Figure 103: Beigene Ltd.: Overall Financials, $Million, 2019-2021
Figure 104: Beigene Ltd.: R&D Expenditure, $Million, 2019-2021
Figure 105: Shanghai Junshi Bioscience Co., Ltd.: Product Portfolio
Figure 106: Shanghai Junshi Bioscience Co., Ltd.: Overall Financials, $Million, 2019-2021
Figure 107: Shanghai Junshi Bioscience Co., Ltd.: R&D Expenditure, $Million, 2019-2021
Figure 108: Shanghai Henlius Biotech, Inc.: Product Portfolio
Figure 109: Shanghai Henlius Biotech, Inc.: Overall Financials, $Million, 2019-2021
Figure 110: Shanghai Henlius Biotech, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 111: Jiangsu HengRui Medicine Co., Ltd.: Product Portfolio
Figure 112: Jiangsu HengRui Medicine Co., Ltd.: Overall Financials, $Million, 2019-2021
Figure 113: Jiangsu HengRui Medicine Co., Ltd.: R&D Expenditure, $Million, 2019-2021
Figure 114: Lee’s Pharmaceutical Limited: Product Portfolio
Figure 115: Lee’s Pharmaceutical Limited: Overall Financials, $Million, 2019-2021
Figure 116: Lee’s Pharmaceutical Limited: R&D Expenditure, $Million, 2019-2021
Figure 117: Incyte Corporation: Product Portfolio
Figure 118: Incyte Corporation: Overall Financials, $Million, 2019-2021
Figure 119: Incyte Corporation R&D Expenditure, $Million, 2019-2021
Figure 120: Biocad: Product Portfolio
Figure 121: CStone Pharmaceuticals: Product Portfolio
Figure 122: CStone Pharmaceuticals: Overall Financials, $Million, 2019-2021
Figure 123: CStone Pharmaceuticals: Revenue (by Region), $Million, 2019-2021
Figure 124: CStone Pharmaceuticals: R&D Expenditure, $Million, 2019-2021
List of Tables
Table 1: Approved PD-1/PDL-1 Inhibitors
Table 2: Snapshot: Approved PD-1/PDL-1 Inhibitors
Table 3: Companies by Region
Table 4: Number of Indication Added Since Launch
Table 5: Combination Regimen with PD-1/PDL-1 Inhibitors
Table 6: Non-Small Cell Lung Cancer (NSCLC): Stage Specific Treatment Options
Table 7: Stage-Wise Colorectal Cancer (CRC) Treatment
Table 8: Systemic Therapy for Distant Recurrence Cases of Colorectal Cancer (CRC)
Table 9: PD-1/PDL-1 Inhibitor by Route of Administration (RoA)
Table 10: Combination Regimes by Development Stage
Table 11: Leading PD-1/PDL-1 Inhibitors and Indications in Combination Therapy
Table 12: Leading PD-1/PDL-1 Inhibitors as Monotherapy and Target Indication
Table 13: U.S. Incidence for Cancer Indications, 2022-2032
Table 14: U.S. Prevalence for Cancer Indications, 2022-2032
Table 15: U.K. Incidence for Cancer Indications, 2022-2032
Table 16: U.K. Prevalence for Cancer Indications, 2022-2032
Table 17: Germany Incidence for Cancer Indications, 2022-2032
Table 18: Germany Prevalence for Cancer Indications, 2022-2032
Table 19: France Incidence for Cancer Indications, 2022-2032
Table 20: France Prevalence for Cancer Indications, 2022-2032
Table 21: Italy Incidence for Cancer Indications, 2022-2032
Table 22: Italy Prevalence for Cancer Indications, 2022-2032
Table 23: Spain Incidence for Cancer Indications, 2022-2032
Table 24: Spain Prevalence for Cancer Indications, 2022-2032
Table 25: Japan Incidence for Cancer Indications, 2022-2032
Table 26: Japan Prevalence for Cancer Indications, 2022-2032
Table 27: GlaxoSmithKline plc: Key Competitors
Table 28: Product Development
Table 29: Partnership and Collaboration
Table 30: Potential Registrational Study Readouts Anticipated Through 2023/2024
Table 31: Bristol-Myers Squibb Company: Key Competitors
Table 32: Product Developments
Table 33: Merger and Acquisitions
Table 34: Arcus Biosciences, Inc.: Key Competitors
Table 35: Product Developments
Table 36: Partnerships and Collaboration
Table 37: Product Developments
Table 38: Partnerships and Collaboration
Table 39: F. Hoffmann-La Roche Ltd: Key Competitors
Table 40: Product Developments
Table 41: Partnership and Collaboration
Table 42: Astra Zeneca PLC: Key Competitors
Table 43: Product Developments
Table 44: Partnership and Collaboration
Table 45: Beigene Ltd.: Key Competitors
Table 46: Product Developments
Table 47: Partnership and Collaboration
Table 48: Shanghai Junshi Bioscience Co., Ltd.: Key Competitors
Table 49: Product Developments
Table 50: Partnership and Collaboration
Table 51: Shanghai Henlius Biotech, Inc.: Key Competitors
Table 52: Product Developments
Table 53: Partnership and Collaboration
Table 54: Jiangsu HengRui Medicine Co., Ltd.: Key Competitors
Table 55: Product Developments
Table 56: Partnership and Collaboration
Table 57: Lee’s Pharmaceutical Limited: Key Competitors
Table 58: Product Developments
Table 59: Product Developments
Table 60: Collaboration and Agreement
Table 61: Product Developments
Table 62: Partnership and Collaboration
Table 63: Product Developments
Table 64: Partnership and Collaboration
Reviews
There are no reviews yet.